Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
Indication: Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer
Trial Number: 06492616
Trial Status: OPEN